Company Focus
Amgen
Latest Amgen News
Pharmaceutical
US biotech major Amgen closed 7% lower on Tuesday after investors questioned whether reductions in bone mineral density might be linked to the use of its investigational obesity candidate MariTide (maridebart cafraglutide, formerly AMG 133) in a Phase I trial. 13 November 2024
Related News
Insights
Company Spotlight
A biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Latest News & Features of interest to Amgen
Pharmaceutical
Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) provided a statistically-significant overall survival benefit at 24 months (23% reduction of risk of death) compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). 2 October 2024
Biotechnology
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Biotechnology
US vaccine company Gritstone bio closed 62% lower after Tuesday’s trading. 2 October 2024
Biotechnology
CAMP4 Therapeutics has announced a new research collaboration with BioMarin Pharmaceutical aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA (regRNA) sequences, which are key elements controlling gene expression. 2 October 2024
Pharmaceutical
Santhera Pharmaceuticals’ rose as much as 5% to .46 francs yesterday after it announced the outcome of the LIONHEART study, confirming vamorolone’s distinctive action also a a mineralocorticoid receptor antagonist, which sets it apart from other corticosteroids. 2 October 2024
Biotechnology
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Biotechnology
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Biotechnology
Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research collaboration and license agreement with Bristol Myers Squibb. 30 September 2024
Biotechnology
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of Amvuttra (vutrisiran), an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 September 2024
Latest In Brief for Amgen
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
13 November 2024
29 October 2024
28 October 2024
26 October 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze